Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Preclinical Research

PETA joins preclinical CROs at SOT to promote animal testing alternatives

27-Mar-2015 - Testing the toxicity of drug candidates in animals is archaic and unreliable according to PETA, which joined preclinical CROs at SOT to put forward alternatives.

Nottingham’s CRO forest thriving: UK Contractors tout new collaboration model

25-Mar-2015 - Some drug industry sponsors shy away from “jack of all trades” contractors according to a recently formed UK CRO network which says smaller firms with specific expertise can win market...

Ebola, eCigarettes and microbiomes: Hot topics at Society of Toxicology annual meeting

24-Mar-2015 - Ebola, electronic cigarettes and microbiomes are opportunities for the preclinical research sector according to delegates at a US industry conference this week.

Harvard-MIT institute partners with Google-backed Calico to study aging-related diseases

18-Mar-2015 - The Broad Institute of MIT and Harvard has entered into a partnership with Calico to study the biology and genetics of aging as part of early-stage drug discovery efforts. 

Animal rights protests have had little impact on preclinical services sector say CROs

17-Mar-2015 - Animal rights protests have not hurt the non-clinical services sector according to leading CROs which say vital drug development work has continued.

Altasciences allies with nonclinical service org to offer more complete early development tools

10-Mar-2015 - Early phase clinical research service provider Altasciences is forming a strategic alliance with ITR Laboratories, a nonclinical services organization, to help more mutual clients customize their drug development programs from...

Exclusive interview

Preclinical prices improving says Huntingdon CEO; firm is mulling US capacity expansion

05-Mar-2015 - Higher capacity utilization is improving prices across the non-clinical research sector according to Huntingdon Life Sciences CEO Brian Cass, who told the preclinical CRO may add scale to US...

CRL’s bottom line continues to be driven by biotech growth, CEO says

05-Mar-2015 - For the second straight year Charles River Laboratories has seen more of its revenue derived from biotech companies than Big Pharma, CEO James Foster told investors at two conferences on...

Huntingdon to be renamed to mark Harlan integration

24-Feb-2015 - Huntingdon Life Sciences has announced it will change its name this year, but has not disclosed what its new moniker will be. So would welcome readers’ suggestions.

Crown Bioscience nabs PDX models, service ops of Molecular Response

17-Feb-2015 - Preclinical CRO Crown is acquiring all of Molecular Response’s existing PDX (patient-derived xenograft) models as well as 8,000 viable human tumors for model development.

Charles River ‘hot in pursuit’ of discovery company acquisitions

16-Feb-2015 - Charles River Laboratories is nearing the acquisition of an early-stage drug discovery company, CEO James Foster told attendees at the Leerink Swann Global Healthcare Conference last week.

Charles River moves forward with plans to re-open Massachusetts preclinical site

11-Feb-2015 - CRO Charles River Laboratories is further exploring the idea of re-opening a preclinical site in Shrewsbury, MA, though it will be more than a year before the site is ready.

Horizon partners on R&D with Rockefeller Uni, Sloan-Kettering, Cornell

02-Feb-2015 - Contract research organization (CRO) Horizon has been selected as a “core facility” for supplying biopharma research tools to academic group the Tri-Institutional Therapeutics Discovery Institute.

AstraZeneca turns to CRISPR for drug discovery; Are you watching Cellectis?

29-Jan-2015 - AstraZeneca has partnered to use the CRISPR genome editing technique across its discovery programmes in a move that puts it on a collision course with French Biotech, Cellectis.

Covance's LabCorp distraction will drive opportunities for CRL, says analyst

23-Jan-2015 - Investment firm William Blair has upgraded preclinical CRO Charles River Laboratories to ‘outperform’ based on strong toxicology demand and the pending acquisition of Covance.

Covance to offer teams of experts for early phase development services

21-Jan-2015 - Covance is looking to speed early drug development by setting up teams of experts to help sponsors bridge their preclinical and clinical development.

Charles River considers re-opening preclinical site in Massachusetts

15-Jan-2015 - CRO Charles River Laboratories (CRL) may re-open a preclinical site in Shrewsbury, MA, if demand for the site perks up in the near future.

Crown expands Precos site to build caucasian cancer expertise

12-Jan-2015 - Crown Biosciences has announced plans to double capacity at a site operated by its Precos division.

Biotech defrauds NIH on $50m flu biologic contract

12-Jan-2015 - Ansun Biopharma will pay out over $2m (€1.6m) after committing fraud against the National Institutes of Health (NIH) to siphon money for cash flow problems.

PPD’s X-Chem signs multi-target collaboration with Janssen

12-Jan-2015 - PPD’s recently acquired biotech company X-Chem is launching a multi-target collaboration with Janssen Biotech. Financial terms of the deal were not disclosed.  

Horizon buys Haplogen chromosome tech for ‘10x’ faster cell production

09-Jan-2015 - Horizon says its £6m (€7.7m) purchase of Austrian biotech Haplogen Genomics means it can produce cell lines ten times faster than before using a haploid gene platform.

13 primates die at Covance Texas facility due to overheating

23-Dec-2014 - On two separate incidents in September and October, a total of 13 primates died at a Covance research facility in Alice, Texas due to hyperthermia.

PPD’s X-Chem licenses cardiovascular drug discovery program to Bayer

19-Dec-2014 - PPD’s biotech company X-Chem has licensed a second drug discovery program to Bayer Pharma, which follows on a multi-target collaboration the companies established in 2012. 

WIL IT software deal speed up US FDA drug evaluations? Yes says Instem

18-Dec-2014 - Regulatory reviewers spend more time managing incoming data than on the drug evaluation process, says Instem which has inked a deal with WIL Research for its nonclinical IT systems.

Horizon Discovery enters crowded CHO cell line market

09-Dec-2014 - Horizon Discovery Group announced Monday that its bioproduction division has shipped its first commercially available engineered CHO (Chinese Hamster Ovary) cell line for use in manufacturing of antibodies.